## BEAM: Beam Therapeutics Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.6% below STRENGTH zone (3.0-6.0%); PEG 7.09 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.59)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy**
- Source: Insider Monkey | 20251222T120913 | Bullish | Relevance: 100%
- Beam Therapeutics (NASDAQ: BEAM) is considered an attractive investment due to promising data from its BEACON trial for sickle cell disease. H.C. Wainwright analyst Patrick Trucchio reaffirmed a Buy rating with an $80 target, citing the potential for risto-cel as an effective cure and the company's differentiated manufacturing process. The stock has received overwhelmingly positive analyst ratings, further supporting its potential.

**2. BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy**
- Source: Yahoo Finance | 20251222T065000 | Bullish | Relevance: 100%
- Beam Therapeutics (NASDAQ:BEAM) is considered an attractive mid-cap healthcare stock, particularly after H.C. Wainwright analyst Patrick Trucchio reaffirmed a Buy rating with an $80 price target, implying a 201% upside. This bullish outlook is based on promising BEACON trial data for risto-cel in sickle cell disease, highlighting its potential to alter hemoglobin levels, cure anemia, and prevent vaso-occlusive crises, along with a highly scalable manufacturing process. Although the consensus 1-year median price target is lower at $43 (62% upside), the stock has received predominantly Buy ratings from analysts.

**3. BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy**
- Source: Finviz | 20251222T120913 | Bullish | Relevance: 96%
- Beam Therapeutics (BEAM) is considered an attractive investment due to positive data from its BEACON trial, which indicates that risto-cel could be a unique and effective treatment for sickle cell disease. H.C. Wainwright analyst Patrick Trucchio has a bullish stance on the stock, projecting a significant upside. The company's differentiated manufacturing process for risto-cel further enhances its competitive edge in the ex vivo hematology space.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Evercore ISI Gr | $35 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Evercore ISI Gr | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.02M) |
| Sells | 5 ($0.65M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 2 |

**Top Holders:**
- FMR, LLC: 11.5% (-9.8%)
- ARK Investment Manag: 10.9% (+24.8%)
- Farallon Capital Man: 9.9% (+0.5%)
- Vanguard Group Inc: 9.1% (-4.7%)
- Blackrock Inc.: 8.0% (+1.8%)

### Key Risks

1. High beta (2.22) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Valuation stretched: PEG 7.1x requires aggressive growth execution.
3. High short interest (23.2%, 9.3 days to cover): squeeze risk or crowded bearish bet.

### Catalysts

- Momentum building: MRS_10 improving +4.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 7.09 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (6.0x), low leverage (D/E 0.36). Institutional flow bullish (6 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.8B |
| Beta | 2.22 |
| 52W Range | $13.53 - $35.25 |
| Short Interest | 23.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 7.09 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -2.8% to 1.6% (+4.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.4pp (needs >3.0% for momentum thesis). MRS_5 at 2.0% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.59% (CS: 90) | Neutral |
| RSI_14 | 59.3 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 1.051x | Above |
| vs SMA50 | 1.102x | Above |
| vs SMA200 | 1.323x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $27.77
- **Stop Loss:** $24.59 (11.5% risk)
- **Target:** $30.95 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 377
- **Position Value:** $10,469.29
- **Portfolio %:** 10.47%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-24 (Est: $-1.12)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.01 | $-1.10 | -8.9% |
| 2025Q2 | $-1.09 | $-1.00 | +8.4% |
| 2025Q1 | $-1.17 | $-1.24 | -5.9% |
| 2024Q4 | $-1.22 | $-1.09 | +10.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*